Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Aren’t Crazy About Hospira, Inc. (HSP) Anymore

Page 1 of 2

Hospira, Inc. (NYSE:HSP) shareholders have witnessed a decrease in activity from the world’s largest hedge funds in recent months.

At the moment, there are many indicators market participants can use to monitor their holdings. Some of the most innovative are hedge fund and insider trading activity. At Insider Monkey, our research analyses have shown that, historically, those who follow the top picks of the best money managers can outclass the broader indices by a very impressive margin (see just how much).

Hospira, Inc. (NYSE:HSP)Just as beneficial, bullish insider trading activity is a second way to break down the stock market universe. There are a variety of stimuli for an upper level exec to downsize shares of his or her company, but only one, very obvious reason why they would initiate a purchase. Various empirical studies have demonstrated the impressive potential of this strategy if you know what to do (learn more here).

Now, it’s important to take a gander at the key action surrounding Hospira, Inc. (NYSE:HSP).

What does the smart money think about Hospira, Inc. (NYSE:HSP)?

Heading into Q2, a total of 21 of the hedge funds we track were long in this stock, a change of -13% from the first quarter. With hedge funds’ capital changing hands, there exists an “upper tier” of key hedge fund managers who were upping their stakes considerably.

According to our comprehensive database, Ariel Investments, managed by John W. Rogers, holds the largest position in Hospira, Inc. (NYSE:HSP). Ariel Investments has a $139.8 million position in the stock, comprising 2.4% of its 13F portfolio. The second largest stake is held by Larry Robbins of Glenview Capital, with a $123.6 million position; 1.3% of its 13F portfolio is allocated to the company. Remaining hedgies with similar optimism include Thomas Ellis and Todd Hammer’s North Run Capital, and Richard S. Pzena’s Pzena Investment Management.

Judging by the fact that Hospira, Inc. (NYSE:HSP) has witnessed bearish sentiment from the entirety of the hedge funds we track, it’s easy to see that there is a sect of hedgies who were dropping their full holdings at the end of the first quarter. It’s worth mentioning that Jim Simons’s Renaissance Technologies dropped the biggest position of the “upper crust” of funds we watch, valued at about $19.2 million in stock.. Malcolm Fairbairn’s fund, Ascend Capital, also dumped its stock, about $14.2 million worth. These bearish behaviors are intriguing to say the least, as aggregate hedge fund interest fell by 3 funds at the end of the first quarter.

How are insiders trading Hospira, Inc. (NYSE:HSP)?

Insider purchases made by high-level executives is best served when the company we’re looking at has seen transactions within the past six months. Over the latest half-year time frame, Hospira, Inc. (NYSE:HSP) has seen zero unique insiders buying, and zero insider sales (see the details of insider trades here).

Let’s also examine hedge fund and insider activity in other stocks similar to Hospira, Inc. (NYSE:HSP). These stocks are Delcath Systems, Inc. (NASDAQ:DCTH), Petmed Express Inc (NASDAQ:PETS), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Alkermes Plc (NASDAQ:ALKS), and Elan Corporation, plc (ADR) (NYSE:ELN). This group of stocks are in the drug delivery industry and their market caps match HSP’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!